Table 3.
Markers of antifibrotic macrophages and potential therapeutic approaches inducing or attracting antifibrotic macrophages or inhibiting the recruitment of profibrotic monocytes.
| Markers | Prospective drug |
|---|---|
| TNF receptor (109, 110) | TNFα (106) |
| CX3CR1 (60) | RANKL (122–124) |
| TNFα (106, 107, 111) | PPARγ agonist (93–100) |
| CXCL10 (59, 117, 118) | IFNγ (59, 125) |
| CXCL9 (117, 118) | IFNα (58, 88) |
| MMP9 (73–75) | Asprin-triggered lipoxin A analogs (126) |
| MMP13 (68, 118) | CCL2 inhibitors (62) |
| Cathepsin K (66, 71, 77, 78) | |
| MERTK(89, 90) | |
| PPARγ (93–100) | |
| MRC1 (120) | |
| MRC2 (121) | |
| MFGE8 (6, 65, 85) | |
| Arg-1 (17) | |
| FIZZ1 (22) |